Professional Media briefs

Quadrant HealthCom's The Female Patient launched a new website at femalepatient.com. The site features a new look, easier navigation and access to audiocasts, videocasts and mobile apps, along with an improved registration/subscription process allowing users to customize, change and update preferences.

Thomson Reuters acquired GeneGo, a San Diego-based firm that provides biology and disease information, analytics and decision support services for pharma R&D. GeneGo will be folded into Thomson Reuters' Healthcare & Science business. The acquisition bolsters Thomson Reuters' drug pipeline competitive intelligence, patents and chemistry offerings with GeneGo's expertise in science, particularly on biologics. In addition to its San Diego headquarters, GeneGo has offices in Moscow and Michigan.

Elsevier dropped the “Cytogenetics” from its Cancer Genetics and Cytogenetics journal, and tapped a new editor-in-chief. The first issue with the shortened title, Cancer Genetics, goes out this month, with Jaclyn Biegel at the helm. The title change reflects a broader aim and scope for the journal, with a new focus on diagnostic applications and genetic predisposition of cancer, according to a statement.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.